Clinical Trial Details

Short Title
Official Title
Trial for Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Description

A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

Participants in this research study are receiving treatment with chemotherapy for Acute Myeloid Luekemia (AML), and therefore at risk of getting an invasive fungal infection. Invasive fungal infections are infections caused by organisms called fungi. The infection is described as invasive when the fungi enters the blood stream and can then spread to different organs in the body. Preventing invasive fungal infections due to chemotherapy is therefore very important for the study treatment success of people with AML.

In this study, researchers want to find out if using a newer antifungal drug called caspofungin (also called Cancidas) will be better than the current standard antifungal drug fluconazole at preventing invasive fungal infections when given to people with AML after receiving chemotherapy study treatment

Approximately 6 people will take part in this study conducted by investigators at the University of Iowa. Approximately 550 people will be enrolled worldwide.

Start Date
November 28, 2011
End Date
November 28, 2021
Gender Preference
None
Age Group
0 - 18 years
Principal Investigator
Ayman El-Sheikh, MD
Contact Info

Julie de la Garza, 319-356-3749

Department
Keywords
acute myeloid luekemia (AML) ; cancer ; caspofungin (Cancidas) ; chemotherapy ; fluconazole ; fungal infections ; IRB#201109830 ; pediatric ;

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks

x